医学
脑室造瘘术
内镜第三脑室造瘘术
脑积水
外科
脑导水管
颅内压
脑室出血
蛛网膜下腔出血
人口
导水管狭窄
胎龄
遗传学
生物
环境卫生
怀孕
作者
Walter Grand,Jody Leonardo,Andrea J. Chamczuk,Adam J. Korus
出处
期刊:Neurosurgery
[Oxford University Press]
日期:2015-08-21
卷期号:78 (1): 109-119
被引量:58
标识
DOI:10.1227/neu.0000000000000994
摘要
Endoscopic third ventriculostomy (ETV) has been used predominantly in the pediatric population in the past. Application in the adult population has been less extensive, even in large neurosurgical centers. To our knowledge, this report is one of the largest adult ETV series reported and has the consistency of being performed at 1 center.To determine the efficacy, safety, and outcome of ETV in a large adult hydrocephalus patient series at a single neurosurgical center. In addition, to analyze patient selection criteria and clinical subgroups (including those with ventriculoperitoneal shunt [VPS] malfunction or obstruction and neurointensive care unit patients with extended ventricular drainage before ETV) to optimize surgical results in the future.We conducted a retrospective review of adult ETV procedures performed at our center between 2000 and 2014.The overall rate of success (no further cerebrospinal fluid diversion procedure performed plus clinical improvement) of 243 completed ETVs was 72.8%. Following is the number of procedures with the success rate in parentheses: aqueduct stenosis, 56 (91%); communicating hydrocephalus including normal pressure hydrocephalus, nonnormal pressure hydrocephalus, and remote head trauma, 57 (43.8%); communicating hydrocephalus in postoperative posterior fossa tumor without residual tumor, 14 (85.7%); communicating hydrocephalus in subarachnoid hemorrhage without intraventricular hemorrhage, 23 (69.6%); obstruction from tumor/cyst, 42 (85.7%); VPS obstruction (diagnosis unknown), 23 (65.2%); intraventricular hemorrhage, 20 (90%); and miscellaneous (obstructive), 8 (50%). There were 9 complications in 250 intended procedures (3.6%); 5 (2%) were serious.Use of ETV in adult hydrocephalus has broad application with a low complication rate and reasonably good efficacy in selected patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI